JP7601375B2 - 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート - Google Patents

長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート Download PDF

Info

Publication number
JP7601375B2
JP7601375B2 JP2020529484A JP2020529484A JP7601375B2 JP 7601375 B2 JP7601375 B2 JP 7601375B2 JP 2020529484 A JP2020529484 A JP 2020529484A JP 2020529484 A JP2020529484 A JP 2020529484A JP 7601375 B2 JP7601375 B2 JP 7601375B2
Authority
JP
Japan
Prior art keywords
ttx
anesthetic
peg
conjugate
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505550A5 (enExample
JP2021505550A (ja
Inventor
ダニエル エス． コヘイン，
チャオ ジャオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021505550A publication Critical patent/JP2021505550A/ja
Publication of JP2021505550A5 publication Critical patent/JP2021505550A5/ja
Priority to JP2024106268A priority Critical patent/JP2024114970A/ja
Application granted granted Critical
Publication of JP7601375B2 publication Critical patent/JP7601375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020529484A 2017-12-01 2018-12-03 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート Active JP7601375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106268A JP2024114970A (ja) 2017-12-01 2024-07-01 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593784P 2017-12-01 2017-12-01
US62/593,784 2017-12-01
PCT/US2018/063573 WO2019109065A1 (en) 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106268A Division JP2024114970A (ja) 2017-12-01 2024-07-01 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021505550A JP2021505550A (ja) 2021-02-18
JP2021505550A5 JP2021505550A5 (enExample) 2021-12-09
JP7601375B2 true JP7601375B2 (ja) 2024-12-17

Family

ID=64734233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529484A Active JP7601375B2 (ja) 2017-12-01 2018-12-03 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート
JP2024106268A Pending JP2024114970A (ja) 2017-12-01 2024-07-01 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106268A Pending JP2024114970A (ja) 2017-12-01 2024-07-01 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート

Country Status (7)

Country Link
US (2) US20210275678A1 (enExample)
EP (1) EP3717017A1 (enExample)
JP (2) JP7601375B2 (enExample)
CN (1) CN111867633B (enExample)
AU (1) AU2018375002B2 (enExample)
CA (1) CA3084034C (enExample)
WO (1) WO2019109065A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090374A4 (en) * 2020-01-17 2024-10-09 Children's Medical Center Corporation MACROMOLECULAR PRODRUGS FOR LIGHT EMITTING DIODES AND THEIR USES
CN113805326A (zh) * 2021-09-18 2021-12-17 吉林大学 原位拉伸多光子激光共聚焦成像仪、实时原位三维观测共混聚合物内部结构的方法
US20250099421A1 (en) * 2023-09-27 2025-03-27 Relevium Medical Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators
CN119345382B (zh) * 2024-12-23 2025-03-21 上海华之沃生物医药科技有限公司 替曲朵辛偶联物、制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
JP2014522816A (ja) 2011-06-22 2014-09-08 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
GB0218830D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic conjugate
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP2015514805A (ja) * 2012-04-23 2015-05-21 ザ チルドレンズ メディカル センター コーポレイション 慢性神経因性疼痛の発症を遅延させるための製剤および方法
NZ710890A (en) * 2013-03-15 2016-11-25 Childrens Medical Ct Corp Neosaxitoxin combination formulations for prolonged local anesthesia
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
CN106310289B (zh) * 2015-06-24 2020-10-13 天津键凯科技有限公司 一种聚乙二醇和麻醉药的结合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
JP2014522816A (ja) 2011-06-22 2014-09-08 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ

Also Published As

Publication number Publication date
US20250195671A1 (en) 2025-06-19
EP3717017A1 (en) 2020-10-07
CN111867633B (zh) 2023-09-22
AU2018375002A1 (en) 2020-07-02
CA3084034A1 (en) 2019-06-06
AU2018375002B2 (en) 2021-11-11
US20210275678A1 (en) 2021-09-09
JP2024114970A (ja) 2024-08-23
CN111867633A (zh) 2020-10-30
CA3084034C (en) 2022-08-16
JP2021505550A (ja) 2021-02-18
WO2019109065A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
US20250195671A1 (en) Covalent anesthetic-polymer conjugates for prolonged local anesthesia
Zhao et al. Polymer-tetrodotoxin conjugates to induce prolonged duration local anesthesia with minimal toxicity
RU2554854C9 (ru) Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
US9974866B2 (en) Protein-poly(2-oxazoline) conjugates for enhanced cellular delivery and transport across biological barriers
Zhang et al. Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management
IL190486A (en) Compounds of hydrophobic polymers undergoing glaciation and containing radical acid and their uses
CA2926169C (fr) Compositions a liberation continue a base d'acide hyaluronique, et leurs applications therapeutiques
Ma et al. Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage
US20090324741A1 (en) Injectable polymer-lipid blend
AU2012289968A1 (en) Stable anti-inflammatory solutions for injection
Wong et al. Evaluation of PolyMPC–Dox Prodrugs in a Human Ovarian Tumor Model
US20190388558A1 (en) Kartogenin derivative-containing polymeric micelle, hyaluronic acid hydrogel, method for producing the same, and use thereof
KR20230050084A (ko) Plga 및 약물을 함유하는 베타-사이클로덱스트린을 포함하는 약물 전달체
WO2010017265A2 (en) Injectable extended release compositions and methods of treating arthritis using same
Doppalapudi et al. Fenoldopam mesylate for treating psoriasis: A new indication for an old drug
Zhang et al. Coixol-Loaded Hydrogels Promote Osteochondral Defect Repair via Modulation of Ferroptosis and Autophagy in Chondrocytes
Li et al. Capsaicin-Loaded Melanin Nanoparticles for Long-Lasting Nociceptive-Selective Nerve Blockade
US20250099598A1 (en) Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators
Machida et al. Development of an Injectable Formulation of a Water-Insoluble Glycyrrhizin Derivative That Potently Inhibits High-Mobility Group Box 1 in Murine Intracerebral Hemorrhage
Ma et al. Glucose‐Facilitated Nanomicelles Cross Peripheral Nerve Barriers to Achieve Drug Delivery to Nerves
Pastukh et al. Injectable hyaluronic acid–metformin conjugate gel for sustained intra‐articular delivery and prevention of post‐traumatic osteoarthritis
Zhong et al. Anti-inflammatory effect of a novel piperazino-enaminone delivered by liposomes in a mouse model of hemophilic arthropathy
Johnston Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues
US20250228765A1 (en) Treating knee joint pain by injecting resiniferatoxin at ultra low doses
KR102062690B1 (ko) 이미다졸-폴리(유기포스파젠) 하이드로겔을 포함하는 척수 손상 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241128

R150 Certificate of patent or registration of utility model

Ref document number: 7601375

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150